Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARG | Q86W56 | 20/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17832115 | 0.91 | PARG (0.65) | PARG | |
| SCHEMBL17832116 | 0.88 | PARG (0.62) | PARG | |
| SCHEMBL17824759 | 0.85 | PARG (1.00) | PARG | |
| SCHEMBL31121986 | 0.84 | PARG (0.72) | PARG | |
| SCHEMBL17863647 | 0.84 | PARG (0.72) | PARG | |
| SCHEMBL17824610 | 0.84 | PARG (1.00) | PARG | |
| SCHEMBL17824810 | 0.82 | PARG (1.00) | PARG | |
| SCHEMBL23644619 | 0.82 | PARG (0.72) | PARG | |
| SCHEMBL17824562 | 0.82 | PARG (1.00) | PARG | |
| SCHEMBL19770699 | 0.81 | PARG (1.00) | PARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180016242-A1 | 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016242-A1 | 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG | PARG, PARP15, PARP12 | PARG 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.